The eradication of cancer remains a vexing problem despite recent advances in our
understanding of the molecular basis of neoplasia. One therapeutic approach that has …

Twenty-eight cases of chylous ascites occurring over the past 20 years are analyzed for
clinical presentation, cause, yield of diagnostic procedure used, and response to therapy. …

OVER THE PAST DECADE, significant advances have been achieved in the chemotherapy
of leuke-mias and lymphomas. Combination chemotherapy regimens and bone marrow …

Background Radiolabeled monoclonal antibodies recognizing B-lymphocyte surface
antigens represent a potentially effective new therapy for lymphomas. We assessed the …

Adoptive immunotherapy with T cells expressing a tumor-specific chimeric T-cell receptor is
a promising approach to cancer therapy that has not previously been explored for the …

CD20 is a nonglycosylated 33 to 37 kD phosphoprotein involved in B-cell signaling that
subserves important functions in the regulation of B-cell proliferation and differentiation. In …

Cellular immune responses have the potential to elicit dramatic and sustained clinical remissions
in lymphoma patients. Recent clinical trial data demonstrate that modification of T cells …

PURPOSE: To evaluate the efficacy and safety of tositumomab and iodine I 131 tositumomab
(Bexxar; Corixa Corp, Seattle, WA, and GlaxoSmithKline, Philadelphia, PA) in patients with …

Four patients with refractory malignant B cell lymphomas were treated with continuous
intravenous (IV) infusions of murine monoclonal antibody (MoAb) 1F5 (anti-CD20) over five to ten …

Background The natural history of follicular lymphoma is believed not to have changed over
the last 30 years. Median survivals have ranged from 7 to 10 years, and the disease is …